Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the National Institutes of Health and others; Alliance A031501 AMBASSADOR ClinicalTrials.gov number, NCT03244384.).
Authors
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Gabriela Perez Burbano (ORCID: https://orcid.org/0000-0002-9810-7150)
- Colleen Watt
- Alan W.C. Tan (ORCID: https://orcid.org/0000-0001-8892-5160)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-0044-9719)
- Min Yuen Teo (ORCID: https://orcid.org/0000-0003-2511-6731)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Jiaoti Huang (ORCID: https://orcid.org/0000-0003-1195-1998)
- Rahul Atul Parikh (ORCID: https://orcid.org/0000-0002-3372-7914)
- Meagan Odegaard
- Daniel M. Geynisman (ORCID: https://orcid.org/0000-0002-1423-5295)
- Nicholas I. Simon (ORCID: https://orcid.org/0000-0003-1259-9201)
- Andrea B. Apolo (ORCID: https://orcid.org/0000-0001-9409-1836)
- Cecilia Mitchell
- Lisa M. Cordes (ORCID: https://orcid.org/0000-0003-3833-4084)
- Scot A. Niglio (ORCID: https://orcid.org/0000-0002-1421-1533)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
- Jonathan E. Rosenberg (ORCID: https://orcid.org/0000-0003-2637-4249)
- Guru Sonpavde (ORCID: https://orcid.org/0000-0002-1010-9611)
- Susan Halabi (ORCID: https://orcid.org/0000-0003-4135-2777)
- Yujia Wen (ORCID: https://orcid.org/0009-0000-5398-4494)
- Bradley A. McGregor (ORCID: https://orcid.org/0000-0002-8298-0289)
- Joseph W. Kim (ORCID: https://orcid.org/0000-0003-2222-3531)
- Michael Woods (ORCID: https://orcid.org/0000-0002-2753-6265)
- Stephanie Berg (ORCID: https://orcid.org/0000-0001-6193-5350)
- Randy F. Sweis (ORCID: https://orcid.org/0000-0002-0497-9637)
- Karla V. Ballman (ORCID: https://orcid.org/0000-0002-4492-0357)
- Parminder Singh (ORCID: https://orcid.org/0000-0002-2851-6805)
- Suzanne Cole (ORCID: https://orcid.org/0000-0001-8390-6315)
- Abhishek Tripathi (ORCID: https://orcid.org/0000-0002-5198-0673)
- Jeannie Hoffman-Censits
- William Y. Kim (ORCID: https://orcid.org/0000-0001-7922-2156)
- Gurkamal Chatta (ORCID: https://orcid.org/0000-0002-3154-9042)
- HOWARD Z. STREICHER (ORCID: https://orcid.org/0000-0003-3683-9804)
- Zachery R. Reichert (ORCID: https://orcid.org/0000-0003-0356-8796)
- Lisa Ley
- Sandy Srinivas
- Helen Moon (ORCID: https://orcid.org/0009-0007-6303-5285)
- Olwen Hahn
Institutions
- National Cancer Institute (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1056/nejmoa2401726
- Citations
- 132
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 75.61
Funders
- Merck
- American College of Radiology Imaging Network
- ECOG-ACRIN Cancer Research Group
- National Institutes of Health
- National Cancer Institute